Colon cancer screening stock Guardant Health is extended from a cup base after a recent breakout. It has a one-of-a-kind cancer blood test.
Research
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
Licensing
12:10 PM ET 06/04/2026
Colon cancer screening developer Guardant Health (GH) recently got powerful backing for one of its blood tests. As a result, shares popped and broke out of a base making it Thursday's IBD 50 Growth Stocks To Watch pick. Guardant Health combines advanced blood and tissue tests and real-world data and artificial intelligence analytics to detect, monitor for recurrence and assist…
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more
Guardant Health secured FDA approval for Guardant360 Liquid CDx, expanding blood-based cancer profiling capabilities.
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid…
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Healthcare stocks are back in focus this month as investors look for strong pipelines and steady growth in a market still driven…
Josh Brown and Sean Russo break down three biotech names in the Best Stocks list.
As new technology capable of detecting dozens of early-stage cancer types with a single blood test hits the market, support for…
